1,421,532 Shares in Century Therapeutics, Inc. $IPSC Bought by Spruce Street Capital LP

Spruce Street Capital LP bought a new position in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) in the fourth quarter, HoldingsChannel reports. The fund bought 1,421,532 shares of the company’s stock, valued at approximately $1,414,000. Century Therapeutics accounts for approximately 0.5% of Spruce Street Capital LP’s portfolio, making the stock its 26th biggest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IPSC. Bank of America Corp DE lifted its position in Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after acquiring an additional 34,466 shares during the last quarter. AQR Capital Management LLC lifted its position in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after acquiring an additional 86,875 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Century Therapeutics by 26.9% in the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after acquiring an additional 38,052 shares during the last quarter. Acadian Asset Management LLC lifted its position in Century Therapeutics by 101.2% in the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after acquiring an additional 142,953 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new stake in Century Therapeutics in the second quarter valued at $25,000. 50.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IPSC has been the subject of a number of research reports. Zacks Research cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. Mizuho initiated coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price target for the company. TD Cowen initiated coverage on shares of Century Therapeutics in a research report on Wednesday, February 25th. They issued a “buy” rating for the company. HC Wainwright boosted their price target on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 24th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.75.

Century Therapeutics Price Performance

IPSC stock opened at $2.30 on Tuesday. The company’s 50 day simple moving average is $2.28 and its 200-day simple moving average is $1.90. The firm has a market capitalization of $414.81 million, a PE ratio of -2.02 and a beta of 1.56. Century Therapeutics, Inc. has a 12 month low of $0.44 and a 12 month high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. As a group, sell-side analysts anticipate that Century Therapeutics, Inc. will post -0.43 earnings per share for the current year.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.